TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07310420: A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

Sponsor: TerSera Therapeutics LLC · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 176 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,419,032

Rescue Site Savings

+$1,602,216

Unlock Full NCT07310420 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07310420 Rescue Dossier →